

Fibrinogen α and γ genes and factor V^{Leiden} in children with thromboembolism: results from 2 family-based association studies

Ulrike Nowak-Göttl,¹ Hartmut Weiler,² Irene Hernandez,² Sabine Thedieck,¹ Tanja Seehafer,³ Thomas Schulte,¹ and Monika Stoll³

¹Pediatric Hematology/Oncology, University of Muenster, Muenster, Germany; ²Blood Research Institute, Blood Center of Wisconsin, Milwaukee; and

³Leibniz-Institute for Arteriosclerosis Research, Genetic Epidemiology of Vascular Disorders, Muenster, Germany

Previous case-control studies showed that genetic variation in the fibrinogen γ gene (*FGG*) increased the risk for deep vein thrombosis (VT) in adults. We investigated the association between the fibrinogen α (*FGA*) and *FGG* haplotypes, the factor V^{Leiden}-mutation, and pediatric VT and thromboembolic stroke (TS) in 2 independent study samples. Association analysis revealed that the *FGA*-H1 and *FGG*-H2 haplotypes were significantly overtransmitted to VT patients (*FGA*-H1, $P = .05$; *FGG*-H2, $P = .032$). In contrast,

the *FGG*-H3 haplotype was undertransmitted ($P = .022$). In an independent study sample, *FGA*-H1 ($P = .008$) and *FGG*-H2 ($P = .05$) were significantly associated with TS. The association of *FGA* and *FGG* haplotypes with VT was more pronounced in FV^{Leiden}-negative families (*FGA*-H1, $P = .001$; *FGG*-H2, $P = .001$), indicating a genetic interaction between both risk factors. The risk-conferring *FGG*-H2 and the protective *FGG*-H3 haplotypes correlated with low (*FGG*-H2) and high (*FGG*-H3) levels of the γ' chain variant, respec-

tively. These results provide independent and novel evidence that *FGA*-H1 and *FGG*-H2 variants are associated with an increased risk of VT and TS in children. The observed negative correlation of genetic VT risk with the plasma levels of the fibrinogen γ' variant suggests that *FGG*-H2 and -H3 haplotypes modify thrombosis risk by controlling the level of this *FGG* splice isoform. (Blood. 2009; 114:1947-1953)

Introduction

Population-based association studies in adults have provided sound evidence for the association of fibrinogen levels with arterial disease, and for the association of fibrinogen gene variations with fibrinogen levels. For example, abnormalities of fibrinogen levels have been reported to affect risk for deep vein thrombosis (VT), particularly in the elderly.^{1,2} However, evidence for the association of disease and fibrinogen gene polymorphisms thought to affect fibrinogen levels is weak.^{3,4} One of the mechanisms by which changes in the fibrin network may contribute to an increased VT risk may hinge on the composition of circulating total fibrinogen levels, particularly the fraction of fibrinogen γ' levels, which in part is influenced by genetic variants residing in the fibrinogen gamma (*FGG*) gene located on the long arm of human chromosome 4 (4q28). A recent study investigating the role of genetic variants in predisposing to VT implicated genetic variants in fibrinogen alpha (*FGA*) and *FGG* genes as genetic determinants for VT through the reduction of circulating plasma fibrinogen γ' levels.⁵ In this study, homozygous carriership of an *FGG* risk haplotype (*FGG*-H2) was associated with an increased risk for VT (odds ratio = 2.4; 95% confidence interval, 1.5-3.9) and, furthermore, reduced fibrinogen γ' levels and reduced ratios of fibrinogen γ' to total fibrinogen. This study was further corroborated by a recent study by Grünbacher et al,⁶ which showed an increased risk for carriers of the *FGG* 10034 TT genotype and VT (odds ratio = 2.01; 95% confidence interval, 1.23-3.31, $P = .006$) in 358 patients and 783 controls, further supporting the importance of genetic variants in *FGG* in the pathogenesis of VT. However, similar studies in VT of pediatric onset are lacking. VT in children is a rare event that probably occurs in neonates and children with underlying conditions, such as cancer, sepsis, autoimmune disease,

and congenital heart disease, or as a consequence of invasive therapeutic procedures. Prominent complicating features of VT in children include lack of thrombus resolution and development of postthrombotic syndrome.⁷⁻⁹ Because of the low incidence of pediatric VT in the general population (0.07-0.14/10 000 population children; $\sim 5/10 000$ hospital admissions of children), studies addressing the impact of genetic modifiers of thrombosis on the incidence of pediatric VT are limited by the relatively small number of patients and therefore often remain inconclusive. Meta-analyses of available data suggest that inherited thrombophilic mutations in coagulation factors identified in adult patients (ie, factor V^{Leiden} [FV^{Leiden}] G1691A, prothrombin G20210A, deficiency of protein S, protein C, and antithrombin) are also the most common genetic determinants of pediatric first VT and ischemic stroke.^{7,9,10} The contribution of fibrinogen gene variation to the incidence of VT in children, and the association with the relative abundance of fibrinogen γ chain isoforms in plasma is unknown. The goal of the current study was to examine the association between genetic variation in *FGG* and *FGA* genes, plasma levels of γ A/ γ' fibrinogen, and thromboembolic disease (VT and nonvascular thromboembolic stroke [TS]) in children.

Methods

In the German study center Muenster, plasma and DNA samples of 244 families of children with VT (Figure 1) and 268 families of children with nonvascular TS (replication cohort),¹¹ that is, samples of the proband, nonaffected brothers or sisters, and biologic parents, were collected

Submitted April 27, 2009; accepted June 4, 2009. Prepublished online as *Blood* First Edition paper, June 10, 2009; DOI 10.1182/blood-2009-04-218727.

The publication costs of this article were defrayed in part by page charge

payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2009 by The American Society of Hematology




Figure 1. Flow chart of patient-parent trio selection. Inclusion and exclusion criteria for patients enrolled in the study are shown.

between January 2002 and December 2007. The present study was performed in accordance with the ethical standards laid down in the updated version of the 1964 Declaration of Helsinki and was approved by the medical ethics committee of the University of Münster, Germany. With written parental consent, term neonates and children with confirmed diagnosis of VT not older than 18 years at onset, biologic brothers and sisters, and available parents were enrolled. Premature birth (\leq 36 gestational weeks), patients older than 18 years at onset, and children with a first ischemic stroke of vascular origin were excluded. In addition, children with missing parents, families with nonpaternity, children lost to follow-up, and patients without parental consent were excluded. Additional exclusion criteria were ongoing liver, renal, or inflammatory diseases, malignancies, and concurrent treatment regimens known to influence fibrinogen levels. Inclusion and exclusion criteria are shown in Figure 1. The replication study sample with pediatric TS and criteria for group assignment to vascular stroke were described in detail elsewhere.^{11,12}

Blood sample collection

Blood sample collection from patients was done in the morning after a 12-hour fasting period (infants fasted 4-6 hours); samples were drawn by peripheral venipuncture into plastic tubes containing one-tenth by volume of 3.8% trisodium citrate (Sarstedt) and were immediately placed on melting ice. The blood samples from patients were collected 6 to 12 months after the acute thrombotic event and at least 6 weeks apart from anticoagulation. Platelet-poor plasma was prepared by centrifugation at 3000g and 4°C for 2 \times 20 minutes, aliquoted in polystyrene tubes, stored at -70°C , and thawed immediately before assay. DNA extraction was performed by a spin column procedure (QIAGEN) according to the manufacturer's instructions.

Fibrinogen and fibrinogen γ' antigen measurements

Total fibrinogen was determined according to the Clauss method using Dade thrombin reagent (Dade-Behring). The test was performed on a Dade

Behring BCS analyzer. Fibrinogen γ' antigen levels were measured by enzyme-linked immunosorbent assay as described previously¹³ with the following modifications: Fibrinogen gamma' chains were detected with the L2B antibody that recognizes both the full-length as well as the truncated form of the γ' chain variant. Standards were prepared from admixtures of purified peak I and II preparations of fibrinogen corresponding to a range between 2% and 20% gamma' content, and all patient samples fell into this concentration range. Horseradish peroxidase-labeled L2B antibody binding to immobilized patient fibrinogen was calculated from the V_{max} of color development over 15 minutes.

Genetic analysis

We identified 7 haplotype tagging single nucleotide polymorphisms (htSNPs) capturing 97.5% of the genetic variation in *FGG* and *FGA* genes using the genotype information from Centre d'Etude du Polymorphisme Humain families available from HAPMAP (www.hapmap.org) and the SNPtagger-tool as implemented in HAPLOVIEW.¹⁴ These htSNPs are composed of 3 SNPs located in *FGG* (rs2066860, rs2066861, rs1049636) and 4 SNPs in *FGA* (rs2070011, rs2070014, rs2070016, rs6050; Thr312Ala), and are in accordance with the htSNPs recently reported by Kardys et al.⁴ Genotyping was performed using the TaqMan allelic discrimination method on a 384-well H7900 (Applied Biosystems) using 2 ng of genomic DNA. For quality control, each plate contained 8 positive Centre d'Etude du Polymorphisme Humain controls and 8 no-template controls to ensure genotyping accuracy. Genotyping efficiency was more than 99.5%. In addition, the presence or absence of the *FV*^{Leiden} mutation was determined using standard laboratory techniques.^{15,16}

Statistical analysis

Hardy-Weinberg equilibrium for each htSNP was tested using χ^2 analysis across all samples. Family-based association was determined using the transmission disequilibrium test (TDT)¹⁷ in 244 trios comprising unaffected parents and the affected child; haplotypes were inferred using the Expectation Maximization Algorithm as implemented in Haplovew (Version 4.0).¹⁴ Significance of association was assessed using a Pearson χ^2 test and corrected for multiple testing using 10 000 permutations as implemented in Haplovew. TDT analyses were repeated after stratification for presence of at least one copy of the *FV*^{Leiden} mutation in the affected child (46 families positive for the *FV*^{Leiden} mutation, 198 families without *FV*^{Leiden}). For correlation analyses between associated *FGG* haplotypes and fibrinogen γ' to total fibrinogen levels in the affected children, the individual haplotypes were reconstructed based on phase because genotype information was available for both parents and the affected child. Distribution of total fibrinogen and fibrinogen γ' levels were assessed using the Kolmogorov-Smirnov test for normalcy to ensure a normal distribution as a prerequisite for parametric analyses. Correlation analyses were performed using one-way analysis of variance, followed by the appropriate post hoc test (Student *t* test). *P* values were adjusted for multiple testing using the Bonferroni method (haplotypes, *FV*^{Leiden} carriership [yes/no], 2 phenotypes = 8 comparisons).

Results

Association between fibrinogen haplotypes and pediatric VT

Genotyping of 244 families for VT (786 persons) showed that the selected 7 htSNPs identified the 4 most common haplotypes in *FGG* and the 5 most common haplotypes in *FGA*, and thus captures 97.5% of the genetic variation present in haplotypes at a frequency more than 1% (Figure 2A). For all SNPs, the distribution of the genotypes was in Hardy-Weinberg equilibrium and similar to those reported by previous studies.^{4,5} Consistent with previous observations,^{4,5} a high degree of linkage disequilibrium was detected between *FGA* and *FGG* (Figure 2B). However, in our study, recombination events were detected between rs2070011 and




Figure 2. LD structure and haplotypes in *FGA* and *FGG* genes. (A) Five *FGA* (H1-H5) and 4 *FGG* (H1-H4) haplotypes are defined by 7 htSNPs capturing 97.5% of the genetic variation in the extended linkage disequilibrium (LD) block harboring *FGA* and *FGG*. (B) LD structure underlying *FGA* and *FGG*.

rs1049636 ($D' = 0.1$) that may affect haplotype structure of the fibrinogen gene cluster (Figure 2A).

Single-point TDT identified 3 significantly associated SNPs with VT, rs6050 [Thr312Ala] (ratio of transmissions to nontransmis-

sions of the overtransmitted allele [T:U] 84:51, $\chi^2 = 8.067$, $P = .004$), rs2070011 (T:U 102:64, $\chi^2 = 8.699$, $P = .003$) in *FGA*, and rs2066861 (T:U 80:52, $\chi^2 = 5.939$, $P = .015$) in *FGG* (Table 1). For each SNP, a significant overtransmission to affected offspring was observed, implying that these SNPs confer a risk for juvenile VT. Subsequent haplotype association analysis revealed that haplotype H1 of the *FGA* gene (AACT) and haplotypes H2 (ATC) were overtransmitted to VT patients, whereas H3 (GCC) of the *FGG* gene was significantly undertransmitted to VT patients (*FGA*: H1, T:U 60:32.6, $\chi^2 = 9.134$, $P = .05$; *FGG*: H2, T:U 85:47, $\chi^2 = 10.939$, $P = .032$; H3, T:U 28:48, $\chi^2 = 5.277$, $P = .022$; Table 2). The associations for H1 in *FGA* and H3 in *FGG* remained significant after permutation testing using 10 000 permutations (*FGA*: H1, $\chi^2 = 9.137$, $P = .024$; *FGG*: H3, $\chi^2 = 8.523$, $P = .037$). These data document that the *FGA*-H1 and the *FGG*-H2 haplotypes are overrepresented in pediatric patients with VT. Conversely, the *FGG*-H3 haplotype was significantly undertransmitted to affected offspring in our pediatric VT cohort and might thus represent a protective haplotype.

The strong linkage disequilibrium detected between the *FGA*-H1 and *FGG*-H2 risk haplotypes (Figure 2B) raised the possibility that these haplotypes are largely coinherited. Phase-adjusted haplotype analysis showed indeed that a recombination event between *FGA*-H1 and *FGG*-H2 had occurred in less than 10% of children.

Replication of association in thromboembolic pediatric stroke

To determine the association of *FGA* and *FGG* haplotypes with thromboembolic nonvascular stroke (TS), a corresponding analysis was performed in an independent family-based cohort of 268 nuclear families with TS. In *FGA*, rs6050 [Thr312Ala] was significantly associated with TS (T:U 95:69, $\chi^2 = 4.122$, $P = .042$). In *FGG*, rs2066861 showed a nonsignificant trend toward association (T:U 96:73, $\chi^2 = 3.13$, $P = .076$), and rs2066860 was significantly associated with TS (T:U 16:05, $\chi^2 = 5.762$, $P = .016$). For

Table 1. Single-point association (TDT) between variants in *FGA* and *FGG* and juvenile VT

SNP ID no.	MAF	Overtransmitted	T:U	χ^2	P
All VT					
rs6050	0.319	A	84:51	8.067	.004*
rs2070016	0.148	G	42:41	0.012	.913
rs2070014	0.154	C	46:31	2.922	.087
rs2070011	0.419	T	102:64	8.699	.003*
rs1049636	0.252	A	62:52	0.877	.349
rs2066861	0.317	T	80:52	5.939	.015*
rs2066860	0.048	C	15:10	1	.317
FVLeiden-negative families					
rs6050	0.315	A	68:38	8.491	.004*
rs2070016	0.142	A	33:30	0.143	.705
rs2070014	0.162	C	38:26	2.25	.134
rs2070011	0.41	T	85:47	10.939	.001*
rs1049636	0.257	A	50:47	0.093	.761
rs2066861	0.321	T	68:40	7.259	.007*
rs2066860	0.048	C	12:08	0.8	.371
FVLeiden-positive families					
rs6050	0.325	A	16:11	0.926	.336
rs2070016	0.171	G	11:08	0.474	.491
rs2070014	0.128	C	08:04	1.333	.248
rs2070011	0.442	T	17:15	0.125	.724
rs1049636	0.237	A	12:04	4	.045
rs2066861	0.295	T	12:10	0.182	.670
rs2066860	0.045	C	03:02	0.2	.655

MAF indicates minor allele frequency; and T:U, ratio of transmissions to nontransmissions.

*P value indicates statistical significance.

Table 2. Association between *FGA* and *FGG* haplotypes and juvenile VT

Block	Haplotype*	Frequency	T:U*	χ^2	P
All VT					
<i>FGA</i> haplotypes					
H1	AACT	0.324	62.0:32.6	9.134	.002‡
H2	GACC	0.28	39.7:51.7	1.576	.209
H3	GATC	0.145	17.0:32.0	4.591	.0321
H4	GGCC	0.138	27.3:23.3	0.317	.574
H5	GACT	0.102	19.0:22.4	0.278	.598
<i>FGG</i> haplotypes					
H1	ACC	0.384	51.0:58.0	0.447	.508
H2	ATC	0.319	60.0:32.0	8.523	.003‡
H3	GCC	0.248	28.0:48.0	5.277	.022
H4	ACT	0.047	9.0: 9.0	0	1
FV^{Leiden}-negative families					
<i>FGA</i> haplotypes					
H1	AACT	0.308	55.0:24.3	11.85	.001‡
H2	GACC	0.281	29.0:52.0	6.532	.011
H3	GATC	0.154	17.0:22.0	0.64	.423
H4	GGCC	0.139	20.0:20.0	0	1
H5	GACT	0.105	17.0:16.7	0.003	.953
<i>FGG</i> haplotypes					
H1	ACC	0.378	37.1:57.0	4.233	.040
H2	ATC†	0.315	54.9:24.0	12.157	.001‡
H3	GCC	0.256	30.9:36.0	0.38	.537
H4	ACT	0.049	6.0:11.0	1.471	.225

T:U indicates ratio of transmissions to nontransmissions.

*The haplotype association for FV^{Leiden}-positive families is not available because of the small sample size.†The H2-ATC haplotype in *FGG* is equivalent to H2-GAT haplotype described by Uitte de Willige et al.⁵ The different annotation is the result of TaqMan primers being designed on the opposite DNA strand.

‡P value indicates statistical significance.

all 3 SNPs, the same allele was overtransmitted to affected offspring as observed in VT. The subsequent haplotype association analysis revealed that haplotype H1 of the *FGA* gene (AACT) and haplotypes H2 (ATC) and H4 (ACT) of the *FGG* gene were significantly associated with TS (*FGA*: H1, T:U 100.7:66.7, $\chi^2 = 6.916$, $P = .008$; *FGG*: H2, T:U 97.7:24.4, $\chi^2 = 3.57$, $P = .05$; H4, T:U 5:19, $\chi^2 = 5.671$, $P = .018$), replicating the haplotype association of *FGA*-H1 and *FGG*-H2 risk haplotypes, but not the putative protective H3 haplotype (T:U 88.4:88.3, $\chi^2 = 0.00$, $P = .993$).

To increase the statistical power of the study, we examined whether combining the VT and TS study populations would strengthen or weaken the association of this haplotype with thromboembolic disease. Given the allele frequency of 0.41 for the risk allele (eg, rs6050 or rs2066861) and a genotype relative risk of 1.5 and 2.0 for heterozygous and homozygous risk allele carriers, respectively, combining all 512 families from both study samples is predicted to enhance the statistical probability to detect association at an $\alpha = 0.05$ through TDT analysis to 79.8%. Single-point TDT analysis of the combined pediatric VT and TS study sample documented significant association of genetic variants in *FGA* and *FGG* at a level of confidence comparable with (rs2070011, $P = .004$) or exceeding (rs6050, $P = .001$; rs2066861, $P = .003$; rs2066860, $P = .018$) the level measured in the VT or TS population alone. Importantly, in the corresponding haplotype analysis, the strength of association of the putative risk haplotypes *FGA*-H1 and *FGG*-H2 with TS was augmented on pooling the TS and VT population (*FGA*-H1: $P = .001$; *FGG*-H2: $P = .002$).

This analysis indicates that the VT-risk haplotypes *FGA*-H1 and *FGG*-H2 also modify the incidence of TS. Conversely, association analysis of *FGG*-H3 and *FGG*-H4 produces divergent outcomes in

VT (H3 protective/undertransmitted; H4 neutral) and TS patients (H3 neutral; H4 protective/undertransmitted).

Genetic interaction between FV^{Leiden} and *FGA* and *FGG* variants

Consistent with existing data,⁸ the FV^{Leiden} mutation is significantly associated with VT in our family cohort (T:U 26:13, $\chi^2 = 4.33$, $P = .037$). To detect potentially confounding interactions between genetic variations in *FGG* and *FGA* and the FV gene, we investigated whether the observed *FGA* and *FGG* haplotype associations with VT were affected by FV^{Leiden} carriership. Therefore, we stratified our cohort on FV^{Leiden} carriership, identifying 46 FV^{Leiden}-positive trios and 198 FV^{Leiden}-negative trios, and repeated the TDT analysis. The association between *FGA* and *FGG* and VT was more pronounced in FV^{Leiden}-negative trios (*FGA*: H1, T:U 55:24, $P = .001$; *FGG*: H2, T:U 55:24, $P = .001$) but was not significant in FV^{Leiden}-positive trios (Tables 1, 2). In addition, the association of *FGG*-H3 with VT was lost in FV^{Leiden}-negative carriers after stratification.

Because the relatively small number ($n = 46$) of FV^{Leiden}-positive families may provide insufficient power to detect association, we repeated the analysis in the combined study samples of VT and TS, comprising 420 FV^{Leiden}-negative and 92 FV^{Leiden}-positive families. TDT analysis of the combined study sample (512 families) resulted in a significant association of genetic variants in *FGA* and *FGG* in FV^{Leiden}-negative trios, in both single point (*FGA*: rs6050, T:U 148:99, $P = .002$; rs2070011, T:U 176:118, $P = .001$; *FGG*: rs2066861, T:U 145:105, $P = .011$; rs2066860, T:U 22:11, $P = .05$) and haplotype analysis (*FGA*: H1, $P = .001$; *FGG*: H2, $P = .007$). Single-point TDT in FV^{Leiden}-positive trios showed a trend for association for rs6050 [Thr312Ala] in *FGA* (T:U 31:19, $P = .089$) and rs2066861 in *FGG* (T:U 31:18,

Table 3. Correlation of *FGG* haplotypes with fibrinogen and fibrinogen γ' content in juvenile VT subjects

Haplotype	n	Fibrinogen	γ' content, %	γ' absolute
H2/H2	26	285.1 \pm 70.7	6.01 \pm 2.25	17.30 \pm 8.00
H2/H1	48	297.6 \pm 107.5	7.67 \pm 3.19	23.82 \pm 17.21
H2/H3	30	291.6 \pm 67.8	8.99 \pm 2.73	26.56 \pm 10.80
H2/H4	6	293.8 \pm 84.3	7.33 \pm 2.83	20.56 \pm 7.47
H1/H1	29	316.1 \pm 125.9	9.78 \pm 2.95	30.76 \pm 13.66
H1/H3	33	253 \pm 67.27	9.01 \pm 3.89	23.08 \pm 19.30
H1/H4	11	296.0 \pm 56.2	9.33 \pm 3.60	27.21 \pm 9.90
H3/H3	19	275.6 \pm 71.3	9.84 \pm 3.15	27.19 \pm 10.71
H3/H4	3	253 \pm 23.1	8.37 \pm 4.13	20.61 \pm 8.83
FV^{Leiden}-negative				
FGG-H2	83	282 \pm 72	7.5 \pm 3	21.4 \pm 11
Other	72	279 \pm 96	9.2 \pm 3.1	25.9 \pm 12
H2 vs other, P		NS	.001	.02
FV^{Leiden} carrier				
FGG-H2	21	307 \pm 125	7.5 \pm 4	23.4 \pm 19
Other	18	300 \pm 75	11 \pm 3	32.8 \pm 11
H2 vs other, P		NS	.002	.06

NS indicates not significant.

$P = .063$), and a significant association for rs1049636 (T:U 32:12, $P = .003$). Pooling VT and TS families stratified for FV^{Leiden} status thus strengthened the association of the risk haplotypes *FGA*-H1 and *FGG*-H2 in FV^{Leiden}-negative trios but failed to compensate for the loss of association in FV^{Leiden} carriers.

Fibrinogen haplotypes and total fibrinogen and fibrinogen γ' levels in VT children

Genetic variation in the *FGG* gene and associated disease risk has been suggested to correlate with plasma concentrations of total fibrinogen, as well as altered absolute and proportional abundance of the fibrinogen γ' isoform in adult patients with VT or ischemic stroke.^{2,5,18} To examine how carriership for *FGG* risk haplotypes correlated with total fibrinogen and γ' levels in the pediatric VT study population, fibrinogen γ' levels and total fibrinogen levels were measured in 207 VT children. Total plasma fibrinogen levels were distributed normally, as judged from Kolmogorov-Smirnov testing. Because genotype information for both parents and the affected child was known, individual haplotypes could be assigned to 98% of all children (n = 202). This enabled parametric statistical analysis to investigate the correlation between haplotype status on one hand, and fibrinogen, fibrinogen γ' , and the percentage of fibrinogen γ' in relation to total fibrinogen, on the other hand.

Total plasma fibrinogen levels were identical in non-H2 carriers (n = 92) and carriers of at least one copy of the *FGG*-H2 risk haplotype (n = 110; 291.1 \pm 87.6 vs 283.0 \pm 92.3, $P = .26$). However, fibrinogen γ' levels and γ' content within total fibrinogen (% γ') were significantly lower in H2 carriers (γ' levels: 22.7 \pm 13.7 vs 26.8 \pm 12.0, $P = .013$; % γ' : 7.63 \pm 3.05 vs 9.46 \pm 3.17, $P = 2.3 \times 10^{-5}$, Bonferroni-corrected $P = .001$). This observation was independent of FV^{Leiden} carriership (data not shown). Carriers of at least one copy of the H3 haplotype (n = 82) compared with noncarriers (n = 120) exhibited significantly lower total plasma fibrinogen levels (270.4 \pm 109.0 vs 299.1 \pm 100.03, $P = .012$; Bonferroni-corrected $P = \text{not significant}$), but increased γ' content within total fibrinogen (% γ' : 9.21 \pm 3.09 vs 7.95 \pm 3.23, $P = .003$, Bonferroni-corrected $P = .024$). These effects were also detected in FV^{Leiden}-negative H3 carriers (fibrinogen: 265.7 \pm 69.2 vs 298.1 \pm 94.5, $P = .009$, % γ' : 9.07 \pm 3.11 vs 7.79 \pm 3.01, $P = .005$, Bonferroni-corrected $P = .038$) but did not reach significance in FV^{Leiden}-positive H3 carriers (fibrinogen: 292.6 \pm 69.3 vs

302.4 \pm 118.9, $P = .388$; % γ' content (%): 9.92 \pm 3.03 vs 8.52 \pm 3.89, $P = .125$).

Homozygous carriership of the *FGG*-H2 risk haplotype was associated with the lowest fibrinogen γ' content, in both absolute and relative terms (Table 3). In compound heterozygous carriers of one H2 allele and any of the other 3 *FGG* haplotypes, absolute and relative γ' levels were on average higher than in H2/H2 homozygotes but lower than in non-H2 carriers (Table 3). Homozygous carriers of the (undertransmitted) *FGG* H3 haplotype show the highest relative fibrinogen γ' content, in part because of overall lower total fibrinogen levels. A similar positive correlation between *FGG*-H3 carrier status and relative abundance of γ' fibrinogen ($P = .001$, Bonferroni-corrected $P = .001$) is seen in compound heterozygotes carrying one H3 allele and one H2 allele. Congruent with studies by others,^{5,19} carriership for any risk haplotype was associated weakly, if at all, with total plasma fibrinogen. These outcomes are consistent with the notion that the VT and TS risk allele *FGG*-H2 is associated with a lower γ' /total fibrinogen ratio, independent of absolute fibrinogen levels.

Discussion

Results of the current genetic study of 512 families with at least one child affected by childhood-onset VT or TS indicate that carriership for the *FGG* H2 haplotype is significantly associated with pediatric VT as well as TS. Measurements of total fibrinogen and the γ' isoform of *FGG* suggest a gene dose effect of *FGG* alleles on the γ' :fibrinogen ratio, independent of absolute plasma fibrinogen levels, with highest relative γ' levels in homozygous *FGG*-H3 carriers, and lowest relative γ' levels in children homozygous for the *FGG*-H2 risk allele. These data are congruent with earlier findings characterizing the *FGG* H2 allele and associated diminished relative levels of γ' fibrinogen as a risk factor for VT in adults.^{5,19} Although a recent case-control study of adults failed to detect an association of the *FGG* H2 risk haplotype with VT, this lack of association might be ascribed to the relatively small sample size (124 cases and 125 controls) and therefore most probably constitutes a type II error (missed association). The current analysis further detected a statistically significant negative correlation of *FGG*-H3 carriership with VT. This finding dovetails evidence from

one previous study²⁰ that the *FGG* H3 haplotype may constitute a protective factor for ischemic stroke. We note that, in the original study by Uitte de Willige et al,⁵ the *FGG* H3 haplotype was also observed more frequently in controls than in VT patients and was associated with a decreased VT risk (odds ratio = 0.8; 95% confidence interval, 0.6-1.0).

In aggregate, these findings suggest that (1) the plasma γ' fibrinogen ratio moderately alters the population risk of VT and ischemic stroke and (2) variations in the plasma γ' /fibrinogen ratio are in part determined by genetic variations in the *FGG* gene, with highest and lowest γ' ratios associated in a gene dose-dependent manner with the *FGG* H3 and H2 alleles, respectively.

Our present findings further show that the most frequent *FGA*-H1 haplotype is overrepresented in pediatric VT patients and in children with nonvascular stroke. In adults, the Ala312Thr polymorphism in *FGA* has been linked to VT^{19,21,22} and poststroke mortality in patients with atrial fibrillation.²³ The *FGA* H1 haplotype is uniquely detected by the presence of the A-allele of the SNP rs6050, which encodes the Ala312 variant of the fibrinogen A α chain, whereas the other 4 major *FGA* haplotypes are composed of the G-allele of rs6050, encoding the Thr312 A α chain. Analysis of clots formed from purified fibrinogen Ala312 and Thr312 showed that Ala312 fibrin fibers are thicker, produce clots with reduced elasticity, and exhibit a higher degree of cross-linking mediated by factor XIII.²⁴

The high degree of linkage disequilibrium between *FGG* and *FGA* gene haplotypes confounds the assignment of disease risk to specific alleles and, in general, complicates establishing the association between genetic variations in the fibrinogen gene locus, level, and composition of fibrinogen. Specifically, studies examining the effect of putative *FGG* H2 risk haplotype associated with diminished γ' chain production relative to total fibrinogen recognized that this haplotype is in a significant portion of persons coinherited with a second polymorphism located in the *FGA* gene (*FGA* Thr312Ala; rs6050). We show that the same is true in our pediatric study population, where the *FGA* H1 variant is coinherited with the *FGG* H2 risk haplotype in 188 of 200 children. These observations highlight that *FGA*-H1 (Ala312) and *FGG*-H2 (low γ'/γ ratio) are in the majority of persons coinherited. As briefly discussed in 2 previous studies,^{5,20} this implies, first, that population-based calculations of the risk conferred by these haplotypes must consider haplotype combinations, rather than a model of independent risk factors. Indeed, comparison of patients carrying the combined *FGA*-H1/*FGG*-H2 haplotypes ($n = 104$) versus non-*FGA*-H1/*FGG*-H2 carriers ($n = 90$) yields identical results as obtained from an analysis of the individual haplotype associations with total fibrinogen (287 ± 85 mg/dL vs 283 ± 92 , $P = \text{not significant}$), absolute levels of γ' (21.8 ± 12 vs 27.2 ± 12 mg/dL; $P = .002$), and $\gamma'/\text{fibrinogen ratio}$ ($7.5\% \pm 3\%$ vs $9.6\% \pm 3.1\%$; $P = .001$).

Recent experiments in mice genetically altered to produce a human γ' fibrin variant capable of high-affinity interaction with thrombin provided direct experimental evidence that $\gamma'/\gamma A$ fibrin exerts an anticoagulant effect that ameliorates the prothrombotic effect of the *FV*^{Leiden} mutation.²⁵ Stratification of families according to *FV*^{Leiden} carriership showed that the genetic risk attributable to *FGA* and *FGG* variants is influenced by the presence or absence of the *FV*^{Leiden}-mutation: the association of *FGG*-H2 with a lower $\gamma'/\text{fibrinogen ratio}$, and with borderline significance ($P = .057$) also of absolute γ' levels, was clearly detectable in both *FV*^{Leiden}-negative and -positive persons and was again independent of total fibrinogen levels (Table 3). The loss of genetic association with disease might be the result of a lack of statistical power to detect a weak association of *FGA/FGG* haplotypes in the presence of a comparably strong risk factor, such as the *FV*^{Leiden} mutation.

However, a different SNP (rs1039636; data not shown) was associated with VT and/or TS exclusively in *FV*^{Leiden} carriers, but not in *FV*^{Leiden}-negative families, indicating that our study was sufficiently powered to detect such positive interactions.

Although the design of the current study inherently does not enable calculations of odds ratios, estimates of the genotype relative risk are consistent with results from population-based association studies that estimate the risk conferred by *FGA*-H1/*FGG*-H2 carriership in the range of 1.1 to 1.8. The *FGA*-H1/*FGG*-H2 risk alleles therefore only modestly affect overall disease incidence and are in all likelihood not informative for predicting thrombosis risk in a given person. However, genotyping for carriership of the *FGA*-H1/*FGG*-H2 alleles could in theory identify a subpopulation of patients whose blood clots exhibit properties distinct from those formed in noncarriers of these alleles. The overall biochemical properties postulated for Ala312 fibrin produced in *FGA* H1 carriers are remarkably similar to the biochemical effects predicted for diminished levels of γ' fibrinogen on clot structure, including partial resistance to fibrinolysis,²⁶ enhanced mechanical clot stiffness, and increased fiber diameter. In addition, thrombin bound to the γ' isoform is relatively resistant to anticoagulant treatment with heparin.^{27,28} Thus, *in vivo* formed clots in *FGA*-H1/*FGG*-H2 persons might combine, possibly in an exaggerated manner, the properties of clots documented *ex vivo* for γ' fibrin or Ala312 fibrin. Fibrin γ' chains not only interact with thrombin but also contain a nearby binding site for fXIII zymogen. The interaction of fibrin-associated fXIII and thrombin may contribute to the altered clot characteristics of fibrin with a high content of γ' chains by altering the kinetics of fXIII activation by thrombin.^{29,30} We note in this context that the fXIII Leu34 variant, which has been identified as a protective trait in thrombotic disorders, produces similar alterations in fibrin structure as high levels of γ' fibrin.²⁹ In vitro experiments with purified fibrinogen suggest that an increased rate of thrombin generation, as probably occurs in *FV*^{Leiden} carriers, may override the biochemical differences between the structures of Ala312 and Thr312 fibrin, or $\gamma A/\gamma A$ and $\gamma'/\gamma A$ fibrin,³¹⁻³⁴ providing a theoretical explanation how the *FV*^{Leiden} mutation might mitigate the risk conferred by *FGA*-H1/*FGG*-H2.

Taken together, the effects of polymorphisms in fXIII, fibrinogen A, and fibrinogen γ chain genes on thrombosis may converge on a common biochemical pathway that defines fibrin structure and susceptibility of formed fibrin to fibrinolysis. The broader significance of these findings for identifying patients at risk and the therapeutic approach to thrombosis remain to be investigated.

Authorship

Contribution: T. Seehafer, S.T., and T. Schulte conducted the genotyping and data management; H.W. and I.H. performed the biochemical studies on fibrinogen gamma' variants; and M.S. and U.N.-G. were responsible for the statistical analyses. All authors had full access to the data and took part in the design, execution, and data analysis, and in writing the report.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Monika Stoll, Genetic Epidemiology of Vascular Disorders, Leibniz-Institute for Arteriosclerosis Research, Domagkstrasse 3, 48149 Muenster, Germany; e-mail: mstoll@uni-muenster.de.

References

- Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briet E, Vandebroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis: a case-control study of plasma levels and DNA polymorphisms—the Leiden Thrombophilia Study (LETS). *Thromb Haemost*. 1994;71:719-722.
- Van Hylckama Vlieg A, Callas PW, Cushman M, Bertina RM, Rosendaal FR. Inter-relation of coagulation factors and d-dimer levels in healthy individuals. *J Thromb Haemost*. 2003;1:516-522.
- Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. *Blood*. 2000;95:1517-1532.
- Kardys I, Uitterlinden AG, Hofman A, Witteman JC, de Maat MP. Fibrinogen gene haplotypes in relation to risk of coronary events and coronary and extracoronary atherosclerosis: the Rotterdam Study. *Thromb Haemost*. 2007;97:288-295.
- Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. *Blood*. 2005;106:4176-4183.
- Grünbacher G, Weger W, Marx-Neuhold E, et al. The fibrinogen gamma (FGG) 10034C>T polymorphism is associated with venous thrombosis. *Thromb Res*. 2007;121:33-36.
- Young G, Albisetti M, Bonduel M, et al. Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies. *Circulation*. 2008;118:1373-1382.
- Nowak-Göttl U, Kurnik K, Krumpel A, Stoll M. Thrombophilia in the young. *Hamostaseologie*. 2008;28:16-20.
- Caruso V, Iacoviello L, Di Castelnuovo A, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. *Blood*. 2006;108:2216-2222.
- Haywood S, Liesner R, Pindora S, Ganesan V. Thrombophilia and first arterial ischaemic stroke: a systematic review. *Arch Dis Child*. 2005;90:402-405.
- Sträter R, Becker S, von Eckardstein A, et al. Prospective assessment of risk factors for recurrent stroke during childhood: a 5-year follow-up study. *Lancet*. 2002;360:1540-1545.
- Nowak-Göttl U, Langer C, Bergs S, Thedieck S, Sträter R, Stoll M. Genetics of hemostasis: differential effects of heritability and household components influencing lipid concentrations and clotting factor levels in 282 pediatric stroke families. *Environ Health Perspect*. 2008;116:839-843.
- Mosesson MW, Hernandez I, Raife TJ, et al. Plasma fibrinogen gamma' chain content in the thrombotic microangiopathy syndrome. *J Thromb Haemost*. 2007;5:62-69.
- Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics*. 2005;21:263-265.
- Junker R, Koch HG, Auberger K, Munchow N, Ehrenforth S, Nowak-Göttl U. Prothrombin G20210A gene mutation and further prothrombotic risk factors in childhood thrombophilia. *Arterioscler Thromb Vasc Biol*. 1999;19:2568-2572.
- Nowak-Göttl U, Sträter R, Heinecke A, et al. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. *Blood*. 1999;94:3678-3682.
- Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). *Am J Hum Genet*. 1993;52:506-516.
- Jood K, Danielson J, Ladenvall C, Blomstrand C, Jern C. Fibrinogen gene variation and ischemic stroke. *J Thromb Haemost*. 2008;6:897-904.
- Carter AM, Catto AJ, Kohler HP, Ariens RA, Stickland MH, Grant PJ. alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism. *Blood*. 2000;96:1177-1179.
- Cheung EY, Utte de Willige S, Vos HL, et al. Fibrinogen gamma' in ischemic stroke: a case-control study. *Stroke*. 2008;39:1033-1035.
- Rasmussen-Torvik LJ, Cushman M, Tsai MY, et al. The association of alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism in the LITE study. *Thromb Res*. 2007;121:1-7.
- Le Gal G, Delahousse B, Lacut K, et al. Fibrinogen Alpha-Thr312Ala and factor XIII-A Val34Leu polymorphisms in idiopathic venous thromboembolism. *Thromb Res*. 2007;121:333-338.
- Carter AM, Catto AJ, Grant PJ. Association of the alpha-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. *Circulation*. 1999;99:2423-2426.
- Standeven KF, Grant PJ, Carter AM, Scheiner T, Weisel JW, Ariens RA. Functional analysis of the fibrinogen Alpha Thr312Ala polymorphism: effects on fibrin structure and function. *Circulation*. 2003;107:2326-2330.
- Mosesson MW, Cooley BC, Hernandez I, Diorio JP, Weiler H. Thrombosis risk modification in transgenic mice containing the human fibrinogen thrombin-binding gamma' chain sequence. *J Thromb Haemost*. 2009;7:102-110.
- Falls LA, Farrell DH. Resistance of gammaA/gamma' fibrin clots to fibrinolysis. *J Biol Chem*. 1997;272:14251-14256.
- Lovely RS, Moadel M, Farrell DH. Fibrinogen gamma' chain binds thrombin exosite II. *J Thromb Haemost*. 2003;1:124-131.
- Frederburgh JC, Stafford AR, Leslie BA, Weitz JI. Bivalent binding to gammaA/gamma'-fibrin engages both exosites of thrombin and protects it from inhibition by the antithrombin-heparin complex. *J Biol Chem*. 2008;283:2470-2477.
- Ariens RA, Lai TS, Weisel JW, Greenberg CS, Grant PJ. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. *Blood*. 2002;100:743-754.
- Mosesson MW. Update on antithrombin I (fibrin). *Thromb Haemost*. 2007;98:105-108.
- Campbell RA, Overmyer KA, Bagnell CR, Wolberg AS. Cellular procoagulant activity dictates clot structure and stability as a function of distance from the cell surface. *Arterioscler Thromb Vasc Biol*. 2008;28:2247-2254.
- Wolberg AS. Thrombin generation and fibrin clot structure. *Blood Rev*. 2007;21:131-142.
- Wolberg AS, Allen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. *Br J Haematol*. 2005;131:645-655.
- Wolberg AS, Monroe DM, Roberts HR, Hoffman M. Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. *Blood*. 2003;100:13008-13013.